Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Draws Line On Procrit Pricing; Will Not Match Amgen Aranesp 40% Discounts

This article was originally published in The Pink Sheet Daily

Executive Summary

Procrit sales are the one weak spot in a strong quarter overall. J&J is moving away from its previous policy of retaining a "level playing field" between Procrit and Aranesp pricing; the strategy now is to have a "reasonably level playing field."
Advertisement

Related Content

Procrit Critical Care Label Expansion Could Fuel Franchise Sales, J&J Says
Procrit Critical Care Label Expansion Could Fuel Franchise Sales, J&J Says
Procrit Could Return To Growth Later This Year, J&J Says
Procrit Could Return To Growth Later This Year, J&J Says
Amgen “Off To Strong Start” Under ASP Reimbursement System
Amgen “Off To Strong Start” Under ASP Reimbursement System
J&J Is Proactive On Procrit Positioning Ahead Of Medicare Part B Changes
J&J Is Proactive On Procrit Positioning Ahead Of Medicare Part B Changes
Future Aranesp Discounts Would Respond To Procrit Price Changes, Amgen Says
Amgen Aranesp Not Affected By Medicare Reimbursement Changes; Sales Up 113%

Topics

Advertisement
UsernamePublicRestriction

Register

PS059094

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel